Literature DB >> 21691326

Osteoarthritis: Local antagonism of endothelin-1 and bradykinin receptors improves OA pain and joint morphology in rats.

Nick Warde.   

Abstract

Entities:  

Year:  2011        PMID： 21691326     DOI： 10.1038/nrrheum.2011.82

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Nociceptive tolerance is improved by bradykinin receptor B1 antagonism and joint morphology is protected by both endothelin type A and bradykinin receptor B1 antagonism in a surgical model of osteoarthritis.

Authors:  Gabriel N Kaufman; Charlotte Zaouter; Barthélémy Valteau; Pierre Sirois; Florina Moldovan
Journal:  Arthritis Res Ther       Date:  2011-05-16       Impact factor: 5.156
  1 in total
  4 in total

1.  BDKRB2 +9/-9 bp polymorphisms influence BDKRB2 expression levels and NO production in knee osteoarthritis.

Authors:  Shuo Chen; Lei Zhang; Ruonan Xu; Yunfan Ti; Yunlong Zhao; Liwu Zhou; Jianning Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-24

Review 2.  Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.

Authors:  Mahjabin Khan; Tao Huang; Cheng-Yuan Lin; Jiang Wu; Bao-Min Fan; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2017-06-07

3.  The effect of bradykinin B2 receptor polymorphisms on the susceptibility and severity of osteoarthritis in a Chinese cohort.

Authors:  Shuo Chen; Yong Zhou; Jun Li; Le-Qun Shan; Qing-Yu Fan
Journal:  J Biomed Biotechnol       Date:  2012-10-03

4.  Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Susceptibility to Osteoarthritis of the Knee: A Case-Control Study and Meta-Analysis.

Authors:  Chin Lin; Hsiang-Cheng Chen; Wen-Hui Fang; Chih-Chien Wang; Yi-Jen Peng; Herng-Sheng Lee; Hung Chang; Chi-Ming Chu; Guo-Shu Huang; Wei-Teing Chen; Yu-Jui Tsai; Hong-Ling Lin; Fu-Huang Lin; Sui-Lung Su
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.